Reaching The Post-Amgen High Bar For Antibody Patents
On Feb. 11, in Amgen Inc. v. Sanofi, the U.S. Court of Appeals for the Federal Circuit revisited the enablement requirements under Title 35 of the U.S. Code, Section 112, after...To view the full article, register now.
Already a subscriber? Click here to view full article